Author: openjargon

Ampol Ltd (ASX: ALD), Megaport Ltd (ASX: MP1) and Northern Star Resources Ltd (ASX: NST) shares are turning heads today.

As we eye the Wednesday lunch hour, two of the ASX 200 heavyweights are charging ahead of the 0.4% gains posted by the S&P/ASX 200 Index (ASX: XJO) while one remains in a trading halt.

Here’s what’s capturing investor interest.

Northern Star shares leap on gold resource boost

Northern Star shares are up 5.3% at time of writing, changing hands for $22.15 apiece.

This strong performance follows the release of the ASX 200 gold stock’s mineral resource and reserve estimate update.

Northern Star reported that its total mineral resources increased by 18.2 million ounces of gold to 88.9 million ounces, after mining depletion.

And the Aussie gold miner’s ore reserves increased by 6.1 million ounces of gold to 28.4 million ounces.

Northern Star shares also look to be catching investor interest, with the miner revealing that it was able to grow its resource at a low-end discovery cost averaging less than $23 per ounce.

Commenting on the growth, Northern Star managing director Stuart Tonkin said:

For the first time, the Hemi Mineral Resources and Ore Reserves have been reported under the Northern Star methodology and economic framework, establishing a consistent, portfolio-wide approach that enhances comparability and underpins future growth opportunities.

Ampol shares gain on ACCC acquisition greenlight

Ampol is also grabbing investor interest today.

Ampol shares are up 2.5% at $34.63 each after the Aussie fuel supplier announced that the Australian Competition and Consumer Commission (ACCC) has approved Ampol’s acquisition of fuel and convenience retailer EG Australia.

The company noted that the approval is conditional on Ampol’s divestment of 41 sites. Ampol said it has entered into a binding agreement to sell the 41 sites to Metro Petroleum.

Citing its strong balance sheet, Ampol said it will cash settle the scrip component of the purchase price. The seller of EG Australia will receive a net cash consideration of approximately $1.115 billion.

“This transaction is a major step in delivering Ampol’s strategy by strengthening our retail network and enhancing our segmented customer offer,” Ampol CEO Matt Halliday said.

Ampol expects to complete the acquisition of EG Australia on 30 June.

Which brings us to…

Megaport shares in second day of trading halt

Joining Ampol and Northern Star shares in making waves today we find Megaport.

Shares in the ASX 200 network services company entered a trading halt yesterday and remain frozen today as the company conducts an $827 million capital raising via a fully underwritten entitlement offer.

Today, the company also reported that is has inked four new AI infrastructure contracts valued at $459 million.

Megaport also narrowed its full year FY 2026 revenue guidance range to between $307 million and $315 million.

The post Why is everyone talking about Megaport, Ampol and Northern Star shares on Wednesday? appeared first on The Motley Fool Australia.

More reading

• Why Acrow, Ampol, Medallion Metals, and Northern Star shares are racing higher
• Ampol shares jump as $1.1 billion deal clears a major hurdle
• 2 major ASX gold companies which can go much higher according to brokers
• Why are Northern Star shares jumping 8% today?
• Megaport shares in focus amid $458.9m AI contract wins and capital raising

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Megaport. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Gold prices have been on the slide since the start of the Middle East conflict, with the share prices of ASX gold producers also heading south as a result.

As the market resets, it can be an opportunity to pick up holdings in gold stocks which might be oversold.

I’ve had a look at the reports coming out of the major broking houses this week and have selected two major gold companies tipped for strong share price gains.

Let’s take a look.

Newmont Corporation (ASX: NEM)

UBS has this week issued a new research report on Newmont, noting that pressures in the gold market generally are mounting.

They predict that gold prices will continue to consolidate around the US$4500 per ounce level.

They added:

At the same time, cost pressures are likely to become more evident in 2Q results, suggesting the recent strong uptrend in consensus earnings for the sector is likely to reverse. Despite broadly attractive spot valuations, we believe gold equities are likely to remain under pressure in the near term.

UBS said against this backdrop they preferred Newmont as the most defensive large-cap miner, driven by conservative 2026 guidance, superior cash returns relative to its peers, and a constructive pathway of catalysts over the next 12 months.

They noted that Newmont had a poor record of meeting guidance in past years, and, “in our view, management is likely to have set conservative expectations in an attempt to build on 2025’s improvement and avoid another guidance miss”.

UBS has a price target of $195 on Newmont shares compared to $151.04 currently.

Northern Star Resources Ltd (ASX: NST)

Shares in Northern Star Resources have spiked this week on news that activist investor Elliott Investment Management had built a stake in the company and was agitating for change.

The investor has published a lengthy report laying out the shortcomings in Northern Star’s recent performance, and is urging the company to undertake a strategic review, appoint new directors and even consider a potential sale.

In response the company said it agreed that it had a superior suite of assets, and also that a search for a new managing director was well underway.

It added:

The Company remains focused on delivering full year guidance and commissioning of the KCGM Mill Expansion, which remains on track to occur in early FY27. Working with the Company’s financial adviser, Goldman Sachs, the Board regularly reviews corporate opportunities, including in relation to managing its existing portfolio of assets and potential broader M&A opportunities.

Citi Research has a price target of $29.70 on Northern Star shares, compared to $22.11 currently.

The post 2 major ASX gold companies which can go much higher according to brokers appeared first on The Motley Fool Australia.

More reading

• Why Acrow, Ampol, Medallion Metals, and Northern Star shares are racing higher
• Why is everyone talking about Megaport, Ampol and Northern Star shares on Wednesday?
• Why are Northern Star shares jumping 8% today?
• Why this activist hedge fund is buying Northern Star shares and what this means for investors
• 5 things to watch on the ASX 200 on Wednesday

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Many of Australia’s top brokers have been busy adjusting their financial models and recommendations. This has led to a number of broker notes being released this week.

Three ASX shares that brokers have named as buys this week are listed below. Here’s why their analysts are feeling bullish on them right now:

4DMedical Ltd (ASX: 4DX)

According to a note out of Bell Potter, its analysts have retained their speculative buy rating on this medical technology company’s shares with an improved price target of $6.00. The broker highlights that 4DMedical has announced plans for a head to head study of its CT:VQ exam vs CT Pulmonary Angiogram (current standard of care) in patients with suspected Pulmonary Embolism (PE). It points out that this is necessary to generate clinical data to support the broader adoption of the 4DX CT:VQ exam for patients not subject to nuclear medicine for the ventilation/perfusion component of the exam. This is important because the total addressable market is estimated at $2.5 billion annually. And while changes to its earnings estimates are modest in the period before FY 2028, it expects exponential adoption beyond then. The 4DMedical share price is trading at $3.83 on Wednesday.

Coles Group Ltd (ASX: COL)

A note out of Macquarie reveals that its analysts have retained their outperform rating on this supermarket giant’s shares with an improved price target of $24.10. The broker believes that trading conditions are tough for retailers right now due to a significant weakening in the outlook for consumer spending. As a result, it has a preference for defensive retailers. This is particularly the case for supermarket operators, with Macquarie believing that consumers will cut back on spending in other categories but not on groceries. The Coles share price is fetching $21.48 at the time of writing.

Pro Medicus Ltd (ASX: PME)

Another note out of Macquarie reveals that its analysts have retained their outperform rating on this health imaging technology company’s shares with a trimmed price target of $221.00. This follows news that Pro Medicus has won a series of contracts for its Visage platform. Macquarie was pleased with the contract wins and highlights that one with TidalHealth includes its cardiology offering. It believes this leaves the company well-placed to achieve its market share estimates by 2030. And with its shares down heavily from their highs, the broker sees considerable upside for investors over the next 12 months. The Pro Medicus share price is trading at $159.12 on Wednesday.

The post Top brokers name 3 ASX shares to buy now appeared first on The Motley Fool Australia.

More reading

• 3 ASX 200 healthcare shares to buy while they’re on sale
• Why AI is making Pro Medicus shares a once-in-a-generation buy
• 5 things to watch on the ASX 200 on Wednesday
• Why 4DMedical shares can return to record highs: Expert
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Bitcoin (CRYPTO: BTC) price is taking a beating on Wednesday.

In earlier trade today, the world’s biggest crypto by market cap had sunk to US$66,127, down more than 7% overnight.

At time of writing, Bitcoin is fetching US$66,683 (AU$93,039), which leaves the token down 6.4% since this time yesterday.

This puts the price down some 12% over the past week, and down a sharp 37% over the last 12 months.

As you may be aware, it was less than a year ago, on 7 October, that the world’s first cryptocurrency notched its all-time high of US$126,198. With the overnight selling, this now sees the Bitcoin price down more than 47% from that record.

Here’s what looks to be causing the latest selling pressure.

Why is the Bitcoin price getting slammed?

There are a number of headwinds working against Bitcoin recently.

First, we have the ongoing Middle East conflict. This is stoking global energy prices and inflation, and leading to the prospect of higher than previously forecast interest rates in the world’s major economies. The Bitcoin price, like many risk assets, tends to perform better in lower rate environments.

Second, it seems that many crypto investors were spooked by news that Bitcoin treasury juggernaut Strategy had sold 32 of its tokens for US$2.5 million.

That looks to be causing some angst, because it was only back in February 2025 that Strategy founder Michael Saylor ‘tweeted’ on X that crypto investors should “never sell your bitcoin”.

While Strategy’s Bitcoin divestment represents only a small part of its total holdings, reportedly valued at around US$66.7 billion, Saylor’s backflip on the “never sell” didn’t go down well with many crypto investors.

According to Pratik Kala, head of research at Apollo Crypto (quoted by The Australian Financial Review):

Now that [Strategy] has sold even a small amount, it’s basically broken the fog. People are now questioning: ‘Well, if the largest holder of bitcoin is selling, what does that mean?’ It will create a little bit of a fear and uncertainty doubt cycle.

Jasper De Maere, OTC trader at Wintermute, added:

The selloff feels triggered by Strategy’s disclosure that it sold 32 BTC. However, reality is that even without this headline, momentum was fading and institutional participation we saw on the OTC desk was grinding back to the lows.

Ryan McMillin, co-founder of Merkle Tree Capital, noted that the Bitcoin price is facing a third stiff headwind.

Namely the rapid rise and investment allure of artificial intelligence.

McMillin said (quoted by the AFR):

If we didn’t have AI flying along like it was last year, then I think bitcoin probably would have gone a lot higher. It sucks a lot of liquidity out of the room, particularly for those with a risk appetite that want to have high-growth assets.

The post Why did the Bitcoin price just plunge more than 7%? appeared first on The Motley Fool Australia.

More reading

• Why is this ASX share crashing 97% today?
• This beaten-up ASX stock just jumped 5%. Here’s why investors are buying again
• Down 30%: Does Bell Potter rate this ASX 200 stock as a buy, hold, or sell?
• 3 ASX 200 healthcare shares to buy while they’re on sale
• Ingenia Communities affirms strong FY26 outlook and development pipeline

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Bitcoin. The Motley Fool Australia has positions in and has recommended Bitcoin. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Opthea Ltd (ASX: OPT) shares have returned to trade with an almighty thud on Wednesday.

The ASX biotech share resumed trading today after being suspended for more than a year, from March 2025 to June 2026.

Unfortunately for its frustrated shareholders, the ASX share is down a massive 97% to 1.8 cents at the time of writing.

Why is this ASX share crashing?

Investors have been selling in response to the failure of an important clinical trial last year and a major reset of the business after a long suspension and strategic review.

Opthea has announced that it is relaunching with a new strategy focused on OPT-302 as a potential treatment for lymphangioleiomyomatosis (LAM).

LAM is a rare, chronic lung disease that primarily affects women. The company believes OPT-302 could have a role because the disease is associated with elevated VEGF-C and VEGF-D signalling, which OPT-302 is designed to inhibit.

This represents a significant change in direction for Opthea from its original focus of retinal diseases.

What is the new plan?

The ASX share is planning a staged development program over around 18 months.

The first stage is already underway and focuses on preclinical biology and inhalation studies. This includes testing whether OPT-302 can be delivered through a nebulised formulation for use in the lungs.

If that work is successful, the company may move into early human studies to assess tolerability and whether the drug affects the relevant biological pathways.

A third stage would then test OPT-302 in patients with LAM, looking for early signs of biological and clinical activity, including measures related to lung function.

Opthea said progression between stages will be subject to board review and predefined scientific, operational, and capital allocation criteria.

Funding position

Opthea advised that it had $31.2 million in cash and cash equivalents at 31 March 2026.

The company estimates that its LAM development program, together with corporate and operational costs, will require approximately $13.1 million over the 18-month period following reinstatement to the ASX.

This suggests the company believes it has enough working capital to pursue its stated objectives for at least 18 months.

Name change proposal

The ASX share has also announced plans to change its name to Ceryvyn Therapeutics.

It notes that this proposed name change is intended to reflect the company’s new strategic focus and future development direction.

Opthea’s executive chair, Dr Jeremy Levin, said:

Opthea is relaunching with a focused strategy centered on OPT-302 and a clear objective: to evaluate a differentiated, mechanism-driven therapeutic opportunity in LAM while leveraging the Company’s substantial existing development, manufacturing and clinical infrastructure.

We believe this approach provides a highly capital-efficient pathway into an area of significant unmet medical need. LAM is a debilitating rare disease with limited treatment innovation and no approved therapies directly targeting aberrant VEGF-C and VEGF-D signaling, biological pathways strongly associated with disease progression and directly targetable by OPT-302.

While Opthea is returning to market with a new plan, it remains an early-stage and high-risk biotech story.

And judging by the share price reaction, they aren’t overly convinced with the change of direction.

The post Why is this ASX share crashing 97% today? appeared first on The Motley Fool Australia.

More reading

• Why did the Bitcoin price just plunge more than 7%?
• This beaten-up ASX stock just jumped 5%. Here’s why investors are buying again
• Down 30%: Does Bell Potter rate this ASX 200 stock as a buy, hold, or sell?
• 3 ASX 200 healthcare shares to buy while they’re on sale
• Ingenia Communities affirms strong FY26 outlook and development pipeline

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Ingenia Communities Group (ASX: INA) shares are having a strong session on Wednesday.

After a difficult year for the stock, investors have responded well to the company’s latest business update.

At the time of writing, the Ingenia share price is up 5% to $3.93.

That gain gives shareholders some relief today. The stock is still down around 24% in 2026 and 32% over the past year.

Let’s take a closer look.

Guidance remains on track

According to the release, Ingenia has reaffirmed its FY26 guidance.

The company said it remains on track to deliver at the top end of its guidance range. That includes EBIT of $180.5 million to $188.7 million, representing growth of around 10% to 15% on FY25.

Ingenia also expects underlying earnings per security (EPS) of 32.5 cents. That reflect an increase of roughly 5% to 10% on FY25.

It seems that after a rough run for the stock, investors are taking some comfort from the guidance holding up.

The company said its business continues to benefit from stable annuity-style cash flows across its land lease and rental communities.

It is also seeing recurring income from tourism operations, while land lease development is expected to support future growth.

Development pipeline keeps growing

The development side of the update also gave investors something to work with.

Ingenia said financial year-to-date sales are up 30% on the prior corresponding period.

The group also has 428 deposits and contracts on hand, which are expected to underpin remaining FY26 settlements and future periods.

Total FY26 settlements are now forecast to land between 560 and 575 homes.

Management said construction programs remain on track, with current projects helping drive settlements across FY27 and FY28.

Ingenia has also been adding to its longer-term development pipeline.

Over FY26 to date, the company has contracted or settled close to 1,600 potential land lease lots across New South Wales, Victoria, and Queensland.

Another 8 sites could add a further 2,200 lots, while 670 lots remain under due diligence.

In total, this lifts Ingenia’s pipeline to more than 8,000 potential land lease lots.

Rental income and holidays remain solid

Furthermore, Ingenia pointed to steady recurring rental income across its core lifestyle, rental, and gardens portfolios.

Occupancy remains high, sitting at 97% in Ingenia Lifestyle, 99% in Ingenia Rental, and 94% in Ingenia Gardens.

The holiday business also appears to be holding up.

Ingenia said Easter trading was resilient, with strong occupancy and rates. Forward bookings are also running 5% to 8% ahead of the prior year.

Foolish bottom line

Without doubt, Ingenia is still trying to tidy up parts of its portfolio.

The company is looking to sell lower-growth assets, which is expected to release about $140 million in capital over the next 6 months.

That could give the group more flexibility as it works through a larger development pipeline.

The post This beaten-up ASX stock just jumped 5%. Here’s why investors are buying again appeared first on The Motley Fool Australia.

More reading

• Ingenia Communities affirms strong FY26 outlook and development pipeline

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

GrainCorp Ltd (ASX: GNC) shares have had a tough time in 2026.

Since the start of the year, the ASX 200 stock has lost almost a third of its value.

Is this a buying opportunity for investors? Let’s see what analysts at Bell Potter are saying about the grain exporter’s shares following their decline.

What is the broker saying?

Bell Potter notes that recent industry data has been released and it isn’t looking favourable for GrainCorp. It said:

The ABARE Jun’26 east coast crop forecast implies a -27% YoY contraction in the east coast winter crop and a -19% YoY contraction in the southeastern canola crop.

Winter East coast crop forecast: ABARE has issued a June 2026-27 east coast winter crop forecast of 23.8mt (vs. 27.2mt in the pcp and a R5YA of 24.2mt). The forecast is predicated on an acreage forecast of 10,370mHa (vs. Jun’24 of 12.0mHa and R5YA of 11.5mHa) and a yield forecast of 2.29t/Ha (vs. Jun’25 of 2.3t/Ha). The acreage forecast is a 7yr low and the yield projection is broadly comparable with the outcome experienced in similar years when the acreage was in the 10,000- 11,000mHa range.

However, the broker highlights that this crop forecast is notoriously unreliable. It explains:

The June forecast is historically the least accurate, on average it has underestimated the final crop size by ~5% over FY11-25 and in the past 5years has underestimated the final crop outcome by ~19%.

Nevertheless, it has still reduced its profit expectations. The broker adds:

NPAT changes are -1% in FY26e and -15% in FY27e reflecting lower crop receipts and lower canola crush volumes, offset in part by stronger crush margins. Our target price is $5.20ps (prev. $5.90ps) reflecting a view that with a drier bias GNC is likely to trade at a discounted multiple.

Is this ASX 200 stock a buy, hold, or sell?

According to the note, Bell Potter has retained its hold rating on GrainCorp’s shares with a reduced price target of $5.20.

This is only marginally higher than the current share price of $5.05.

Commenting on its investment thesis, Bell Potter said:

In the June report we noted a seven year low in east coast winter crop acreage sown and a seven year low in southeastern (VIC/NSW/SA) canola production. Key months are now the August-September window, which are crucial for yield development in a potentially dryer backdrop.

The post Down 30%: Does Bell Potter rate this ASX 200 stock as a buy, hold, or sell? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Wednesday
• 4 ASX 200 shares tipped to rise 30% or more in the year ahead
• Buy, hold, sell: Australian Agricultural Company, Graincorp, Ricegrowers shares
• Here are the top 10 ASX 200 shares today
• ASX 200 consumer staples shares outperformed again last week

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

A severe sector-wide downturn has put ASX healthcare 200 shares under significant pressure this year driven by macroeconomic pressures, a weaker US dollar, rising inflation, higher cost-of-living, and regulatory uncertainty.

The S&P/ASX 200 Health Care Index (ASX: XHJ) is the worst performing sector by far in 2026 and has significantly unperformed the broader index. The decrease has pushed many major ASX healthcare companies to multi-year lows.

At the time of writing, the ASX 200 Health Care Index is down around 34% for the year to date and 47% lower than 12 months ago.

For context, the wider S&P/ASX 200 Index (ASX: XJO) is largely flat for the year to date and 3% higher than this time last year.

Sector wide declines might look concerning, but I think it presents a great opportunity for investors to buy into ASX 200 healthcare shares for cheap.

Here are three stocks that I’d buy today, while they’re on sale.

ResMed Inc (ASX: RMD)

ResMed shares have fallen to a two-year low this week and are down 28% for the year so far. The global leader in sleep health was swept up in the general sector-wide ASX healthcare sell-off. Its latest third-quarter earnings update also came in softer than expected, which didn’t help lessen declining sentiment. But I think the ASX 200 healthcare share is now oversold and below fair value. Sleep disorders require long-term management, and as a global leader, ResMed has a powerful position in a large (and growing) market. According to Market Index data, brokers have a strong buy consensus on ResMed shares and tip a 67% upside to an average $43.38 target price, at the time of writing.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH)

Fisher & Paykel shares have rebounded around 14% since hitting a two-year low in mid-May, but the shares have still got some more room to run before they return to 2025-levels. At the time of writing, the shares are still down around 6% for the year to date and they’re 11% lower than 12 months ago. Investors have been buying this medical device company’s shares following the release of its strong FY26 result last month, which showed investors that the business is sound. The ASX 200 healthcare company reported a 14% increase in total operating revenue and a 24% increase in NPAT. Brokers rate the shares as a strong buy and tip a potential 21% upside to an average $36.90 target price, at the time of writing.

Pro Medicus Ltd (ASX: PME)

Pro Medicus shares have rebounded around 21% since the health imaging technology company announced a new contract win. In late May, the ASX 200 healthcare company confirmed it has signed a five-year, A$28 million contract renewal with Allegheny Health Network (AHN). The increase has helped recoup some, but not all losses shed by the company over the past year. Pro Medics shares are still around 28% lower for the year to date and 43% below their trading price this time last year. The company’s US subsidiary also won two $40 million five-year contract renewals back in early March. It looks like we’ll see plenty more out of the company over the next 12 months, too. The majority of brokers rate the ASX 200 healthcare shares as a strong buy and tip an 18% upside to an average $188.51 target price, at the time of writing.

The post 3 ASX 200 healthcare shares to buy while they’re on sale appeared first on The Motley Fool Australia.

More reading

• Why AI is making Pro Medicus shares a once-in-a-generation buy
• Here are the top 10 ASX 200 shares today
• Which tech share is the ‘most defensively positioned software business’ on the ASX?
• Are CSL and ResMed shares buys at 52-week lows?
• Why DroneShield, Pro Medicus, SRG Global, and Woodside shares are charging higher today

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Ingenia Communities Group (ASX: INA) share price is in focus as the company reaffirmed it expects to deliver its FY26 result at the top of its guidance, forecasting 10%–15% EBIT growth and a 5%–10% rise in underlying EPS on FY25. It’s also expanding its development pipeline, with over 3,400 new home sites acquired or secured in the second half.

What did Ingenia Communities report?

• FY26 settlements anticipated in the range of 560 to 575 homes, including joint ventures
• EBIT guidance for FY26 set at $180.5 to $188.7 million, up 10% to 15% on FY25
• Underlying earnings per share targeted at 32.5c to 34.0c, representing 5% to 10% growth
• Development pipeline expanded to over 3,400 potential home sites acquired or secured in 2H26
• Recurring income and occupancy remain high across lifestyle, rental, and gardens assets

What else do investors need to know?

Ingenia Communities is continuing to benefit from stable, annuity-style cash flows, drawing on its established land lease and rental homes, and cash from tourism operations. Year-to-date FY26 sales are up 30% on the prior period, while there are 428 deposits and contracts on hand, supporting both this year’s and future settlements.

The group is also selling lower-growth assets to free up around $140 million in capital, which will be redeployed to support further development. Construction programs remain on schedule, with new projects started at sites across NSW, Victoria, and Queensland.

What did Ingenia Communities management say?

CEO John Carfi said:

The Group is well positioned to deliver at the top of guidance and to navigate changing market conditions. The business is underpinned by a strong and stable revenue base from our established land lease and rental communities and resilient holidays performance. Long-term demand drivers – an ageing population, lack of housing supply and desire for affordable living – remain firmly in place, with the commencement of new projects providing a runway for settlements growth.

A sale process for lower growth assets has commenced and is expected to release approximately $140 million in capital over the next six months, with a further update to be provided at the upcoming result.

What’s next for Ingenia Communities?

Ingenia expects to finalise the sale of non-core assets in the next six months, freeing funds to accelerate development and target ongoing growth. Its 5-Year Plan aims to achieve 10–15% compound annual growth in settlements to FY29, supported by a large pipeline of home sites and ongoing high occupancy across the portfolio.

Management remains confident in stable demand drivers and will provide further detail with its full FY26 results due 25 August 2026.

Ingenia Communities share price snapshot

Over the past 12 months, Ingenia Communities shares have declined 32%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 3% over the same period.

View Original Announcement

The post Ingenia Communities affirms strong FY26 outlook and development pipeline appeared first on The Motley Fool Australia.

More reading

• If I could buy just 1 ASX stock in June, it’d be this cheap ASX 200 share
• Superloop upgrades FY26 earnings guidance and unveils new strategy
• Megaport secures 4 new AI contracts, announces capital raise
• 5 things to watch on the ASX 200 on Wednesday
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The All Ordinaries Index (ASX: XAO) is up 0.3% today, with plenty of help from this surging ASX All Ords gold stock.

The outperforming stock in question is Medallion Metals Ltd (ASX: MM8).

Medallion Metals shares closed yesterday trading for 40.5 cents. In early morning trade on Wednesday, shares are changing hands for 43 cents apiece, up 6.2%.

Here’s what’s grabbing investor interest.

ASX All Ords gold stock jumps on historic drill results

Medallion Metals shares are charging higher after the miner announced more high-grade gold results from the Lounge Lizard gold deposit, located within its Forrestania Gold Project in Western Australia.

The latest results stem from the ASX All Ords gold stock’s ongoing evaluation of previously unreleased historical drilling at the deposit, conducted in the 1990s.

Citing the two rounds of outstanding high-grade results from Lounge Lizard that it has already reported, the miner said the latest results give it a better understanding of the geological layout.

Having integrated the legacy drilling from 212 drill holes into recently completed 3D geological modelling, Medallion Metals noted this will “greatly enhance” its exploration efforts moving forward in a system that remains open down-dip and along strike.

Top results reported from the deposits included 11 metres at 6.94 grams of gold per tonne from 50 metres, and 3 metres at 13.5g/t Au from 17 metres.

The ASX All Ords gold stock is aiming for an initial Mineral Resource Estimate (MRE) for the Forrestania Gold Project deposits in the third quarter of 2026. It noted the potential for mine life extensions beyond the current Feasibility Study.

What did Medallion Metals management say?

Commenting on the results boosting the ASX All Ords gold stock today, Medallion Metal managing director Paul Bennett said, “This latest phase of validation continues to strengthen our understanding of the Lounge Lizard mineralised system and the continuity of high-grade mineralisation beneath the historical open pit.”

Bennett added:

By integrating validated historical drilling with field mapping, the team has improved confidence in the updated geological interpretation across multiple lodes, with these results continuing to highlight the potential for additional high-grade ounces at Lounge Lizard.

Importantly, Lounge Lizard is continuing to reinforce its potential to become a near term production source as we look to build the Forrestania production profile alongside other high-grade deposits across the project tenure with the ultimate objective of extending mine life and increasing production rates beyond those outlined in the Feasibility Study.

With today’s intraday gains factored in, the Medallion Metals share price is up 43.3% since this time last year, outpacing the 3.5% one-year gains delivered by the All Ords.

The post Guess which ASX All Ords gold stock is leaping higher today on more high-grade results appeared first on The Motley Fool Australia.

More reading

• Why Codan, Medallion, Megaport, and Mineral 260 shares are storming higher today

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.